Halama Anna, Kulinski Michal, Kader Sara Abdul, Satheesh Noothan J, Abou-Samra Abdul Badi, Suhre Karsten, Mohammad Ramzi M
Department of Physiology and Biophysics, Weill Cornell Medicine-Qatar, Qatar-Foundation, P.O Box: 24144, Doha, Qatar.
Translational Research Institute, Academic Health System, Hamad Medical Corporation, PO Box 3050, Doha, Qatar.
J Transl Med. 2016 May 18;14(1):140. doi: 10.1186/s12967-016-0897-6.
Diabetes testing using saliva, rather than blood and urine, could facilitate diabetes screening in public spaces. We previously identified 1,5-anhydro-D-glucitol (1,5-AG) in saliva as a diabetes biomarker. The Glycomark™ assay kit is FDA approved for 1,5-AG measurement in blood. Here we evaluated its applicability for 1,5-AG quantification in saliva.
Using pooled saliva samples, we validated Glycomark™ assay use with a RX Daytona(+) clinical chemistry analyser. We then used this set-up to analyse 82 paired blood and saliva samples from a diabetes case-control study, for which broad mass spectrometry-based characterization of the blood and saliva metabolome was also available. Osmolality was measured to account for potential variability in saliva samples.
The technical variability of the read-outs for the pooled saliva samples (CV = 2.05 %) was comparable to that obtained with manufacturer-provided blood surrogate quality controls (CV = 1.38-1.8 %). We found a high correlation between Glycomark assay and mass spectrometry measurements of serum 1,5-AG (r(2) = 0.902), showing reproducibility of the non-targeted metabolomics results. The significant correlation between the osmolality measurements performed at two independent platforms with the time interval of 2 years (r(2) = 0.887), also indicates the sample integrity. The assay read-out for saliva was not correlated with the mass spectrometry-based 1,5-AG saliva measurements. Comparison with the full saliva metabolome revealed a high correlation of the saliva assay read-outs with galactose.
Glycomark™ assay read-outs for saliva were stable and replicable. However, the signal was dominated by galactose, which is biochemically similar to 1,5-AG and absent in blood. Adapting the 1,5-AG kit for saliva analysis will require enzymatic depletion of galactose. This should be feasible, since the assay already includes a similar step for glucose depletion from blood samples.
使用唾液而非血液和尿液进行糖尿病检测,有助于在公共场所开展糖尿病筛查。我们之前已鉴定出唾液中的1,5-脱水-D-葡萄糖醇(1,5-AG)为糖尿病生物标志物。Glycomark™检测试剂盒已获美国食品药品监督管理局(FDA)批准用于血液中1,5-AG的测量。在此,我们评估了其在唾液中1,5-AG定量分析的适用性。
我们使用混合唾液样本,通过RX Daytona(+)临床化学分析仪验证了Glycomark™检测的使用。然后,我们利用该装置分析了来自一项糖尿病病例对照研究的82对血液和唾液样本,该研究还提供了基于广泛质谱分析的血液和唾液代谢组特征。测量了渗透压,以考虑唾液样本中的潜在变异性。
混合唾液样本读数的技术变异性(CV = 2.05%)与制造商提供的血液替代质量控制样本的变异性(CV = 1.38 - 1.8%)相当。我们发现Glycomark检测与血清1,5-AG的质谱测量之间具有高度相关性(r(2) = 0.902),表明非靶向代谢组学结果具有可重复性。在两个独立平台上,间隔2年进行的渗透压测量之间的显著相关性(r(2) = 0.887),也表明了样本的完整性。唾液检测读数与基于质谱的1,5-AG唾液测量结果不相关。与完整唾液代谢组的比较显示,唾液检测读数与半乳糖高度相关。
Glycomark™检测唾液的读数稳定且可重复。然而,信号主要由半乳糖主导,半乳糖在生化性质上与1,5-AG相似且在血液中不存在。使1,5-AG试剂盒适用于唾液分析需要对半乳糖进行酶促消耗。这应该是可行的,因为该检测已经包括了从血液样本中消耗葡萄糖的类似步骤。